Additional effects using progestins in mares on levels of thyroid hormones and steroids in neonates.

The risk of pregnancy loss in mares leads to the use of exogenous hormones to help pregnancy maintenance. The objective was to evaluate the proportion of thyroid hormones and steroids in neonates, in the following postpartum period, born to mares fed with synthetic progesterone and to verify the existence of a correlation between the level of progesterone between mother and neonate. Twenty-seven mares and their foals were used. The animals were divided into 5 experimental groups: group 1 (control, without hormonal supplementation), group 2 (random samples fed to 120 days of pregnancy with long-term progesterone), group 3 (mares fed with short-term progesterone as of 280.º day of pregnancy), group 4 (mares fed with long-term progesterone as of 280.º day of pregnancy) and group 5 (mares fed with synthetic hormone [altrenogest] as of 280.º day of pregnancy). The animal's blood collection took place immediately after parturition for the hormonal measurement. The hormones measured in neonates were total T3, free T4, TSH, progesterone and cortisone. In mares, only levels of progesterone. The groups of neonates showed no difference on levels of total T3, free T4, TSH and progesterone. There was no difference on levels of progesterone in mares among the groups. Neonates from groups 4 and 5 had higher and lower cortisone levels, respectively. No neonate showed clinical change. There was also no correlation between levels of progesterone in mares and foals. Thus, hormonal supplementation with long-term progesterone as of 280 days of pregnancy leds to an increase in the neonate's cortisone levels, in the meantime, supplementation with altrenogest as of 280 days of pregnancy caused a decrease on cortisone levels in foals, despite clinical signs have not been observed on these animals.

Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial.

Canine pituitary-dependent hypercortisolism (PDH) management with trilostane usually demands lifelong therapy. The greater the dose needed, the greater the risk of side effects. Selegiline therapy has been previously described but not commonly used for PDH treatment. The present work aimed to assess the efficacy of selegiline and trilostane combined therapy for canine PDH treatment. Fifteen client-owned dogs diagnosed with spontaneous PDH were enrolled. The patients were treated with trilostane (Tri group, n = 8, initial dose of 0.5 mg/kg, PO, q12h), or with trilostane and selegiline (Tri + Sel group, n = 7, initial trilostane dose of 0.5 mg/kg, PO, q12h and selegiline 1 mg/kg, PO, q24h). Dogs underwent clinical examination, serum biochemical analysis, urinalysis, abdominal ultrasound, and eACTH and post-ACTH cortisol measurements on treatment days zero (D0), 30 (D30), 90 (D90), and 180 (D180). There was a lack of adverse effects due to the combined therapy. Both groups showed a similar clinical response and lower post-ACTH cortisol levels at the study's end. There was no significant difference in trilostane dosage at D180 between groups. There was no documented increase in either right or left adrenal gland thickness in the Tri + Sel group in contrast with patients in the Tri group. However, there was no statistical difference between the groups regarding eACTH at D0 and D180. Patients in the Tri + Sel group achieved better serum triglycerides control at the end of the study. The association of selegiline with trilostane might be a feasible therapy for canine PDH; however, its eventual advantages need larger studies.

Is Methylprednisolone Acetate-Related Insulin Resistance Preventable in Cats?

Methylprednisolone acetate (MPA) is often prescribed to cats despite being recognized eventually as diabetogenic. To assess MPA-related insulin resistance and evaluate the efficacy of metformin or an obesity and diabetes mellitus (O&D) adjuvant diet as protective factors, a randomized clinical trial was conducted with 28 owned cats undergoing glucocorticoid therapy. A single MPA dose of 20 mg intramuscularly was administered to each cat. Controls (n = 10) received only MPA. In the diet group (n = 9), replacement of their habitual diet by ad-libitum feeding of a feline commercial O&D diet (Equilíbrio O&D, Total Alimentos ADM) was made. In the metformin group (n = 9), metformin chlorhydrate 25mg/cat PO/q24h was administered for 30 days. All patients were clinically evaluated at baseline (T0), day 15 (T15), and day 30 (T30) and blood draw for complete blood count, serum biochemistry, and determination of insulin concentrations. Fasting Insulin Sensitivity Index (SI), Amended Insulin to Glucose Ratio (AIGR), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), and Homeostatic Model Assessment of beta-cell function (HOMA-B) were calculated based on fasting glycemia and insulinemia. All groups showed significantly higher levels (P < .05) of neutrophils, albumin, glucose, cholesterol, triglycerides, and serum insulin at T15. Patients in the metformin group showed also higher SI, AIGR, and HOMA-IR results at T15. Also, at T15, reduced levels (P < .05) of eosinophils, lymphocytes, and creatinine were documented in all groups. An MPA single dose induced changes in insulin sensitivity in cats; however, neither metformin nor O&D feeding used in this study was effective as protective factors against MPA-related insulin resistance.

Adrenal function evaluation in critically ill dogs with low doses of synthetic ACTH / Avaliação da função adrenal em cães portadores de doenças críticas com baixa dose de ACTH sintético

The hypothalamus-pituitary-adrenal axis function may be impaired in patients with critical illnesses, especially cases of sepsis, named critical illness-related corticosteroid insufficiency (CIRCI). This study examined the function of the hypothalamic-pituitary-adrenal axis in normal dogs (n = 10) and dogs with critical diseases (n = 16), through determinations of endogenous ACTH (adrenocorticotropic hormone), basal cortisol and cortisol after stimulation in low doses of synthetic ACTH (1.0µg/kg/IV). The stimulation test with ACTH dose tested was verified as effective for evaluation of adrenal function in healthy and sick dogs. Ill dogs differed from healthy dogs by presenting higher basal cortisol values. Eight sick dogs presented a decrease in endogenous ACTH, basal cortisol, or Δ-cortisol. No significant differences were found between the control groups and critically ill dogs for the values of endogenous ACTH, cortisol after stimulation or Δ-cortisol. We concluded that the stimulation test with low-dose ACTH was effective for evaluation of adrenal function, as well as the fact that a considerable portion of critically ill dogs studied here, especially with sepsis, had evidence of inadequate corticosteroid response to stress.(AU)

A função do eixo hipotálamo-hipófise-adrenal pode estar comprometida em pacientes com doenças críticas, em especial casos de sepse, sendo nomeada de Insuficiência Corticosteroide Relacionada à Doença Crítica (ICRDC). O presente trabalho analisou a função do eixo hipotálamo-hipófise-adrenal em cães normais (n=10) e cães portadores de doenças críticas (n=16), por meio de determinações de ACTH (hormônio adrenocorticotrófico) endógeno, de cortisol basal e de cortisol após estímulo com baixa dose de ACTH sintético (1,0µg/kg/IV). Constatou-se que o teste de estimulação com ACTH na dose testada se mostrou eficaz para avaliação da função adrenal em cães sadios e doentes. Os cães doentes diferiram dos sadios ao apresentar valores maiores de cortisol basal. Oito cães doentes apresentaram diminuição do ACTH endógeno, do cortisol basal ou do Δ-cortisol. Não foram encontradas diferenças significativas entre os grupos Controle e Criticamente enfermos para os valores de ACTH endógeno, cortisol após estimulação ou Δ-cortisol. Concluiu-se que o teste de estimulação com baixa dose de ACTH mostrou-se eficaz para avaliação da função adrenal, assim como, uma parcela considerável da população de cães críticos aqui estudados, em especial com sepse, apresentaram evidências de resposta corticosteroide inadequada frente ao estresse.(AU)

Eficiência da mensuração de progesterona salivar para identificar a ovulação em cadelas / Efficiency of salivary progesterone measurement to identify the ovulation in bitches

Vários autores enfatizaram a importância do monitoramento do ciclo estral em cadelas e citaram exemplos de como realizar tal procedimento. O objetivo deste estudo foiavaliar a técnica de dosagem de progesterona salivarem cadelas para identificar a ovulação nesta espécie. Para composição do grupo experimental, foram utilizadas 13 cadelas, de diferentes raças (sem raça definida, Buldogue Inglês, Bernesse Mountain Dog) e diferentes idades (11 meses a 9 anos). Amostras de sangue e saliva foram colhidas simultaneamente em todos os animais, a partir dos primeiros sinais clínicos de proestro. Amostras salivares foram obtidas com o uso de dispositivo comercial específico (Salivette®). Este método foi eficaz, visto ter tornado possível obter volume suficiente para dosagem de progesterona na grande maioria das amostras (100 μL para dosagens em duplicata). As concentrações de progesterona no soro foram determinadas pela técnica de radioimunoensaio e na saliva por enzimaimunoensaio, ambas com kits comerciais. Observou-se uma relação linear crescente e positiva entre a progesterona sérica e salivar (r=0,704; p<0,0001) em cadelas. Uma das cadelas apresentou ciclo anovulatório, no qual, durante 13 dias, as concentrações séricas de progesterona sérica se mantiveram entre 1,67 e 3,76 ng/mL e as concentrações salivares de progesterona entre 19,55 e 236,77 pg/mL. Conclui-se que as concentrações de progesterona salivarmensuradas pela técnica de enzimaimunoensaio podem ser utilizadas para avaliar a ocorrência ou ausência de ovulação em cadelas.

Several authors have emphasized the importance of monitoring estrous cycle in bitches and mentioned technique examples of how it can be done. The aim of this study was to evaluate the salivary progesterone quantification technique in order to identify ovulation in this species. To compound the experimental group, 13 bitches of different breeds (no specific breed, English Bulldog, Bernesse Mountain Dog)and different ages (from 11 months to 9 years old) were used. Blood and saliva samples were collected simultaneously in all animals, starting about the first day of proestrus clinical signs. Salivary samples were collected with a specific commercial device (Salivette®). This method was effective, since it has become possible to obtain enough volume in almost all samples to quantify salivary progesterone (100 μL for duplicate quantification). Serum progesterone was quantified by radioimmunoassay and salivary progesterone by enzyme immunoassay, both of them with commercial kits. There was an increasing, linear and positive correlation between salivary and serum progesterone (r=0.704; p<0.0001) in bitches. One of the animals had an anovulatory cycle, in which, for 13 days, seric progesterone levels were maintained between 1.67 and 3.76 ng/mL and salivary progesterone levels were maintained between 19.55 and 236.77 pg/mL. It was concluded that salivary progesterone levels measured by enzyme immunoassay is a technique that can be used to evaluate the presence or absence of ovulation in bitches.

Differences in blood glucose increase between horses receiving xylazine and detomidine for surgical and non-surgical clinical procedures / Diferenças no aumento da glicemia entre equinos recebendo xilazina e detomidina para procedimentos clínicos cirúrgicos e não-cirúrgicos

The aim of this prospective randomized clinical study was to compare blood glucose and cortisol levels between horses receiving xylazine and detomidine for surgical and non-surgical procedures. Horses from non-surgical groups received 0.5 mg/kg of xylazine (GX group, n=5) or 0.01 mg/kg of detomidine (GD group, n=5) for gastroscopic examination. Horses from the surgical groups received similar doses of xylazine (AX group, n=7) or detomidine (AD group, n=7), followed by anesthetic induction with 2 mg/kg of ketamine and 0.05 mg/kg of diazepam for an arthroscopic procedure under isoflurane anesthesia. Blood samples were obtained prior to the alpha-2 agonist administration (baseline) and after 10, 30, 60 and 90 minutes. All groups had a significant increase in blood glucose from 30 to 90 minutes after alpha-2 agonist administration, compared to baseline. After receiving the alpha-2 agonist, the AD group had blood glucose levels (118-150 mg/dL) significantly higher than GD (99-119 mg/dL) and AX (97-116 mg/dL) groups. Cortisol had no significant changes within a group. However, the AX group had cortisol levels (3.6-3.7 mg/dL) significantly lower than GX group (5.4-5.7 mg/dL) from 30 to 90 minutes after xylazine administration. We concluded that blood glucose levels were when detomidine was administered for surgical procedure, compared to xylazine also for surgical procedure, and non-surgical procedure. Serum cortisol was minimally affected by administration of xylazine and detomidine regardless procedures were surgical or non-surgical.

O objetivo deste estudo clínico, radomizado e prospectivo, foi comparar as concentrações sanguíneas de glicose e cortisol entre equinos recebendo xilazina e detomidina para procedimentos cirúrgicos e não-cirúrgicos. Os equinos dos grupos nãocirúrgicos receberam 0,5 mg/kg de xilazina (grupo GX, n=5) ou 0,01 mg/kg de detomidina (grupo GD, n=5) para realização de exame gastroscópico. Os equinos dos grupos cirúrgicos receberam doses semelhantes de xilazina (grupo AX, n=7) ou detomidina (grupo AD, n=7), seguindo-se a indução anestésica com 2 mg/kg de cetamina e 0,05 mg/kg de diazepam para realização de procedimento artroscópico durante anestesia com isofluorano. As amostras de sangue foram coletadas antes da administração do alfa-2 agonista (basal) e após 10, 30, 60 e 90 minutos. Todos os grupos tiveram um aumento significativo da glicemia, a partir de 30 até 90 minutos da administração do alfa-2 agonista, em relação ao basal. Após receber o alfa-2 agonista, o grupo AD apresentou glicemia (118-150 mg/dL) significativamente maior que os grupos GD (99-119 mg/dL) e AX (97-116 mg/dL). Não houve diferenças significativas da concentração de cortisol dentro de cada grupo. Entretanto, o grupo AX apresentou níveis de cortisol (3,6-3,7 mg/dL) significativamente mais baixos que o grupo GX (5,4-5,7 mg/dL), a partir de 30 até 90 minutos da administração de xilazina. Concluímos que a glicemia apresentou valor mais elevadoapós a administração de detomidina para realização de procedimento cirúrgico, comparado à xilazina administrada também para procedimento cirúrgico, e para procedimento não-cirúrgico. A concentração sérica de cortisol foi minimamente influenciada pela administração de xilazina e detomidina independentemente dos procedimentos serem cirúrgicos ou não-cirúrgicos.